Zobrazeno 1 - 9
of 9
pro vyhledávání: '"C M Abitbol"'
Publikováno v:
Journal of Crohn's and Colitis. 16:i429-i430
Background Extraintestinal manifestations (EIM) occur in up to 50 % of patients with inflammatory bowel disease (IBD) and are associated with significant morbidity and diminished quality of life. Ustekinumab (UST) and vedolizumab (VDZ) are effective
Autor:
A Levartovsky, I Cohen, C M Abitbol, M Yavzori, E Fudim, O Picard, U Kopylov, S Ben-Horin, B Ungar
Publikováno v:
Journal of Crohn's and Colitis. 16:i451-i451
Background Vedolizumab trough serum levels have been associated with clinical and endoscopic response in patients with inflammatory bowel disease (IBD), albeit findings have not been conclusive. A recent study demonstrated that higher trough vedolizu
Publikováno v:
Journal of Crohn's and Colitis. 16:i382-i382
Background Acute severe ulcerative colitis (ASUC) is considered a medical emergency and is associated with high rates of colectomy and even death. Intra-venous corticosteroids serve as first line therapy for ASUC. Patients who fail to respond will pr
Publikováno v:
Gastroenterology Week; 2/13/2024, p903-903, 1p
Publikováno v:
Gastroenterology Week; 2/17/2023, p1356-1356, 1p
Autor:
Deehan, Gerald A., Hauser, Sheketha R., Wilden, Jessica A., Truitt, William A., Rodd, Zachary A.
Publikováno v:
Frontiers in Behavioral Neuroscience; Aug2013, Vol. 7, p1-13, 13p
Publikováno v:
Frontiers in Behavioral Neuroscience; Jun2013, Vol. 7, p1-8, 8p
Autor:
Hoffman, Allison C., Evans, Sarah E.
Publikováno v:
Nicotine & Tobacco Research; Mar2013, Vol. 15 Issue 3, p622-632, 11p
Publikováno v:
Annals of the New York Academy of Sciences; 1996, Vol. 781 Issue 1, p424-436, 13p